WINNIPEG, MB, Aug. 25, 2020 /CNW/ - Waverley Pharma Inc.
("Waverley Pharma" or the "Company") (TSXV: WAVE), an emerging
Canadian pharmaceutical company, is pleased to announce that its
wholly owned Irish subsidiary, Waverley Pharma Europe Limited, has
been granted marketing authorization for Pemetrexed in Spain and Bortezomib in Italy.
About Pemetrexed
Pemetrexed is an injectable chemotherapy product used in the
treatment of pleural mesothelioma and non-small cell lung cancer
along with other indications. The Company has obtained marketing
authorization for this product in numerous countries and is in the
process of filing for market authorization in additional countries
across Europe.
About Bortezomib
Bortezomib is an injectable chemotherapy product used to treat
multiple myeloma and mantle cell lymphoma along with other
indications. The Company has obtained marketing authorization for
this product in numerous countries and is in the process of filing
for market authorization in additional countries across
Europe.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on
the development and commercialization of safe, effective, and
affordable cancer therapeutics in the European Union, United Kingdom and North American market. The
Company, through its subsidiary, is currently selling three generic
oncology products in the United
Kingdom, namely capecitabine, temozolomide and erlotinib. In
addition, the Company is developing two generic oncology products
in Europe, namely pemetrexed and
bortezomib and additional products in the
United States. Waverley Pharma is committed to providing
patients with affordable prescription medicines that lower
healthcare costs and provide a better quality of life. For more
information on Waverley Pharma please visit
www.waverleypharma.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements
contained in this press release that are not statements of
historical fact, including, without limitation, statements
containing the words "believes", "may", "plans", "will",
"estimates", "continues", "anticipates", "intends", "expects" and
similar expressions, may constitute "forward-looking information"
within the meaning of applicable Canadian and U.S. federal
securities laws (such forward-looking information and
forward-looking statements are hereinafter collectively referred to
as "forward-looking statements"). Forward-looking statements and
other estimates, analysis and opinions of management of the Company
made in light of its experience and its perception of trends,
current conditions and expected developments, as well as other
factors which the Company believes to be relevant and reasonable in
the circumstances. Inherent in forward-looking statements are known
and unknown risks, uncertainties and other factors beyond the
Company's ability to predict or control that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements, and as such, readers are cautioned not
to place undue reliance on forward-looking statements. Such risk
factors include, among others, the Company's potential product
revenues, stage of development, additional capital requirements,
risks associated with obtaining regulatory approval to market the
Company's products, the ability to protect its intellectual
property, dependence upon collaborative partners, changes in
government regulation or regulatory approval processes, and rapid
technological change in the industry. Such statements are based on
a number of assumptions which may prove to be incorrect, including,
but not limited to, assumptions about: general business and
economic conditions; the impact of changes in Canadian-US dollar
and other foreign exchange rates on the Company's revenues, costs
and results; the timing of the receipt of regulatory and
governmental approvals for the Company's research and development
projects; the availability of financing for the Company's
commercial operations and/or research and development projects, or
the availability of financing on reasonable terms; the
uncertainties associated with the acceptance and demand for new
products and market competition. The foregoing list of important
factors and assumptions is not exhaustive. The Company undertakes
no obligation to update publicly or otherwise revise any
forward-looking statements or the foregoing list of factors, other
than as may be required by applicable legislation. Additional
discussion regarding the risks and uncertainties relating to the
Company and its business can be found in the Company's other
filings with the applicable Canadian securities regulatory
authorities.
SOURCE Waverley Pharma Inc.